Page 705 - Read Online

Page 10 of 10 Merle et al. Hepatoma Res 2020;6:60 I http://dx.doi.org/10.20517/2394-5079.2020.52

sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Barcelona (Spain): European-Society-for-Medical-
Oncology (ESMO) Congress; 2019.
21. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, et al. Brivanib in patients with advanced hepatocellular carcinoma who were
intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013;31:3509-16.
22. Lencioni R, Montal R, Torres F, Park JW, Decaens T, et al. Objective response by mRECIST as a predictor and potential surrogate end-
point of overall survival in advanced HCC. J Hepatol 2017;66:1166-72.
23. Kudo M, Finn RS, Qin SK, Han KH, Ikeda K, et al. Analysis of survival and objective response in patients with hepatocellular carcinoma
in a phase III study of lenvatinib (REFLECT). San Francisco: Gastrointestinal Cancers Symposium (ASCO GI) Congress; 2019.
24. Bruix J, Huang LP, Nakajima K, Han GH, Meinhardt G, et al. Time to progression and response rate are not reliable surrogate endpoints
for overall survival in hepatocellular carcinoma: an analysis from the phase 3 RESORCE trial. San Francisco: American Association for
the Study of Liver Diseases (AASLD) Congress; 2018.
25. Llovet JM, Montal R, Villanueva A. Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol
2019;70:1262-77.
26. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
27. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of
sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66.
28. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after
failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014;312:57-67.
29. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, et al. Ramucirumab as second-line treatment in patients with advanced
hepatocellular carcinoma: analysis of REACH trial results by child-pugh score. JAMA Oncol 2017;3:235-43.
30. Rimassa L, Assenat E, Peck-radosavljevic M, Pracht M, Zagonel V, et al. Tivantinib for second-line treatment of MET-high,
advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Lancet Oncol
2018;19:682-93.